ONCBeiGeneFinished
Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · Mantle Cell Lymphoma · Marginal Zone Lymphoma · Waldenstrom Macroglobulinemia
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.7
2 insiders sold shares within a month
Since Aug 3, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 96 (final count)
- Started
- Oct 15, 2019
- Main results expected
- Jan 9, 2026
- Fully finished
- Jan 9, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Recurrence and change in severity of treatment-emergent Adverse Events (AEs) of interest.
Measured over: 24 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.7, since 2026-08-03, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04116437 · record last updated 2026-01-28 · checked 2026-11-09 15:47 UTC